ALSTON & BIRD LLP for NOVO NORDISK INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 8, American Taxpayer Relief Act (R&D tax credit) of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Health Issues HCR
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), Prevention and Public Health Fund, and USPSTF diabetes screening standards;H.R. 1074 and S 539 Diabetes Clinical Care Commission Act of 2013; human growth / rare disorders awareness; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); gestational diabetes; H.R. 351 and S. 351 IPAB Repeal of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER FISE | — |
| JOYCE E GRESKO New | — |
| ELINOR HILLER | — |
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETER FISE | — |
| JOYCE E GRESKO New | — |
| ELINOR HILLER | — |
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| MARILYN K YAGER | — |
Budget/Appropriations BUD
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8 FY14 Senate Budget Resolution; Modernizing cost estimates with respect to preventive health legislation (CBO scoring); National Diabetes Prevention Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Pharmacy PHA
Issues regarding Pharmaceutical Traceability Enhancement Code (Rx TEC) Act and discussion draft on serialization (track and trace).
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.